4.7 Article

Validation of High-Sensitivity Troponin I in a 2-Hour Diagnostic Strategy to Assess 30-Day Outcomes in Emergency Department Patients With Possible Acute Coronary Syndrome

Journal

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Volume 62, Issue 14, Pages 1242-1249

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2013.02.078

Keywords

acute myocardial infarction; ADAPT; APACE; chest pain; high-sensitivity troponin I; TIMI

Funding

  1. Queensland Emergency Medicine Research Foundation
  2. Christchurch Heart Institute
  3. Health Research Council
  4. Heart Foundation of New Zealand
  5. Christchurch Emergency Care Foundation
  6. Abbott Diagnostics
  7. Alere
  8. Swiss National Science Foundation
  9. University Basel
  10. Swiss Heart Foundation
  11. Roche
  12. Siemens
  13. University Hospital Basel
  14. Queensland Emergency Medical Research Foundation
  15. Radiometer Pacific
  16. Boehringer-Ingelheim
  17. Pfizer
  18. AstraZeneca
  19. Stiftung fur kardiovaskulare Forschung Basel
  20. 8sense
  21. Abbott
  22. Critical Diagnostics
  23. Nanosphere
  24. Department of Internal Medicine
  25. Beckmann Coulter
  26. Hospira
  27. Sanofi-Aventis
  28. National Heart Foundation (New Zealand)
  29. Swiss National Science Foundation [PASMP3-136995]
  30. University of Basel
  31. Professor Max Cloetta Foundation
  32. Department of Internal Medicine, University Hospital Basel
  33. Lilly and Bayer
  34. Lilly
  35. Bayer
  36. Boston Scientific
  37. Cordis
  38. Medtronic
  39. Sanofi
  40. Schering-Plough
  41. Pathology Queensland Study
  42. Research and Education Trust Fund
  43. Aventis
  44. Beckman Coulter
  45. Health Research Council of New Zealand
  46. Roche Diagnostics
  47. National Health & Medical Research Council (Australia) for Cardiovascular Research
  48. Brahms
  49. Novartis
  50. Medicines Company
  51. Emergency Care Foundation
  52. Health Research Council (New Zealand)
  53. Swiss National Science Foundation (SNF) [PASMP3_136995] Funding Source: Swiss National Science Foundation (SNF)

Ask authors/readers for more resources

Objectives The study objective was to validate a new high-sensitivity troponin I (hs-TnI) assay in a clinical protocol for assessing patients who present to the emergency department with chest pain. Background Protocols using sensitive troponin assays can accelerate the rule out of acute myocardial infarction in patients with low-risk (suspected) acute coronary syndrome (ACS). Methods This study evaluated 2 prospective cohorts of patients in the emergency department with ACS in an accelerated diagnostic pathway integrating 0- and 2-h hs-TnI results, Thrombolysis In Myocardial Infarction (TIMI) risk scores, and electrocardiography. Strategies to identify low-risk patients incorporated TIMI risk scores = 0 or <= 1. The primary endpoint was a major adverse cardiac event (MACE) within 30 days. Results In the primary cohort, 1,635 patients were recruited and had 30-day follow-up. A total of 247 patients (15.1%) had a MACE. The finding of no ischemic electrocardiogram and hs-TnI <= 26.2 ng/l with the TIMI 0 and TIMI <= 1 pathways, respectively, classified 19.6% (n = 320) and 41.5% (n = 678) of these patients as low risk; 0% (n = 0) and 0.8% (n = 2) had a MACE, respectively. In the secondary cohort, 909 patients were recruited. A total of 156 patients (17.2%) had a MACE. The TIMI = 0 and TIMI <= 1 pathways classified 25.3% (n = 230) and 38.6% (n = 351), respectively, of these patients as low risk; 0% (n = 0) and 0.8% (n = 1) had a MACE, respectively. Sensitivity, specificity, and negative predictive value for TIMI 0 in the primary cohort were 100% (95% confidence interval [CI]: 98.5% to 100%), 23.1% (95% CI: 20.9% to 25.3%), and 100% (95% CI: 98.8% to 100%), respectively. Sensitivity, specificity, and negative predictive value for TIMI <= 1 in the primary cohort were 99.2 (95% CI: 97.1 to 99.8), 48.7 (95% CI: 46.1 to 51.3), and 99.7 (95% CI: 98.9 to 99.9), respectively. Sensitivity, specificity, and negative value for TIMI <= 1 in the secondary cohort were 99.4% (95% CI: 96.5 to 100), 46.5% (95% CI: 42.9 to 50.1), and 99.7% (95% CI: 98.4 to 100), respectively. Conclusions An early-discharge strategy using an hs-TnI assay and TIMI score <= 1 had similar safety as previously reported, with the potential to decrease the observation periods and admissions for approximately 40% of patients with suspected ACS. (Advantageous Predictors of Acute Coronary Syndromes Evaluation [APACE] Study, NCT00470587; A 2hr Accelerated Diagnostic Protocol to Assess patients with chest Pain symptoms using contemporary Troponins as the only biomarker [ADAPT]: a prospective observational validation study, ACTRN12611001069943) (C) 2013 by the American College of Cardiology Foundation

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available